Picture of Sharp Therapeutics logo

SHRX Sharp Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-73.48%
3m-74.9%
6m-56.23%
1yr-60.66%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-639.59%
Return on Equity-165%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Sharp Therapeutics EPS forecast chart

Profile Summary

Sharp Therapeutics Corp. is a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases. Its discovery platform combines high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines. Its technology includes CoreX assay technology, AlloChem compound libraries, and mine data system and machine learning layer. Its advanced programs include a small molecule that prevents the degradation of the neuroprotective protein progranulin, thus increasing progranulin levels preventing neurodegeneration, and a small molecule that restores activity of mutated GCase protein (mutation and loss of activity of GCase is the genetic cause of Gaucher’s disease).

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    September 30th, 2024
    Incorporated
    October 4th, 2021
    Public Since
    August 4th, 2023
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconTSX Venture Exchange
    Shares in Issue
    8,545,200

    SHRX Share Price Performance

    Similar to SHRX

    Picture of Hemostemix logo

    Hemostemix

    ca flag iconTSX Venture Exchange

    Picture of Innovotech logo

    Innovotech

    ca flag iconTSX Venture Exchange

    Picture of Marvel Biosciences logo

    Marvel Biosciences

    ca flag iconTSX Venture Exchange

    Picture of Medicure logo

    Medicure

    ca flag iconTSX Venture Exchange

    Picture of MustGrow Biologics logo

    MustGrow Biologics

    ca flag iconTSX Venture Exchange

    FAQ